Presentation is loading. Please wait.

Presentation is loading. Please wait.

INTERNATIONAL. CAUTION: For distribution only in markets where CoreValve® is approved. Not for distribution in U.S., Canada or Japan. Medtronic, Inc. 2011.

Published byVictor O’Connor’ Modified over 9 years ago

Similar presentations

Presentation on theme: "INTERNATIONAL. CAUTION: For distribution only in markets where CoreValve® is approved. Not for distribution in U.S., Canada or Japan. Medtronic, Inc. 2011."— Presentation transcript:

1 INTERNATIONAL. CAUTION: For distribution only in markets where CoreValve® is approved. Not for distribution in U.S., Canada or Japan. Medtronic, Inc. 2011. All Rights Reserved. Axel Linke University of Leipzig Heart Center, Leipzig, Germany Ulrich Gerckens Gemeinschaftskrankenhaus Bonn, Bonn, Germany Peter Wenaweser University Hospital Bern, Bern, Switzerland Corrado Tamburino Ferrarotto Hospital, University of Catania, Catania, Italy Johan Bosmans University Hospital Antwerp, Antwerp Belgium Stephen Brecker St. George’s Hospital, London, United Kingdom (on behalf of the ADVANCE Investigators) UC201206161 EE.

2 INTERNATIONAL. CAUTION: For distribution only in markets where CoreValve® is approved. Not for distribution in U.S., Canada or Japan. Medtronic, Inc. 2011. All Rights Reserved. Disclosure Statements Axel Linke, MD PI, Medtronic CoreValve ADVANCE Study Medtronic CoreValve Proctor customary travel and expenses only

3 INTERNATIONAL. CAUTION: For distribution only in markets where CoreValve® is approved. Not for distribution in U.S., Canada or Japan. Medtronic, Inc. 2011. All Rights Reserved. Transcatheter Aortic Valve Implant (TAVI) enables treatment of aortic valve stenosis without open-heart surgery. Balloon-expandable TAVI - superior to standard medical therapy in inoperable patients - non-inferior to surgical AVR in high-risk patients with AS in a randomized controlled trial. Neither balloon-expandable or self expanding TAVI have been studied in a rigorous, monitored, independently adjudicated, ‘real world’ study. CoreValve ADVANCE | Background

4 INTERNATIONAL. CAUTION: For distribution only in markets where CoreValve® is approved. Not for distribution in U.S., Canada or Japan. Medtronic, Inc. 2011. All Rights Reserved. CoreValve ADVANCE | Background Medtronic CoreValve ® System Porcine pericardial tissue valve sutured into a self expanding nitinol frame Supra-annular valve position preserves circularity at level of valve function 18Fr catheter delivery system 3 valve sizes

5 INTERNATIONAL. CAUTION: For distribution only in markets where CoreValve® is approved. Not for distribution in U.S., Canada or Japan. Medtronic, Inc. 2011. All Rights Reserved. CoreValve ADVANCE | Objective The objective of the CoreValve ADVANCE study is to evaluate the safety efficacy clinical outcome according to VARC of percutaneous aortic valve implantation using the Medtronic CoreValve System in consecutive ‘real world’ patients with severe aortic stenosis considered inoperable or high risk for conventional AVR by the local ‘HEART TEAM’.

6 INTERNATIONAL. CAUTION: For distribution only in markets where CoreValve® is approved. Not for distribution in U.S., Canada or Japan. Medtronic, Inc. 2011. All Rights Reserved. CoreValve ADVANCE | Methods 1,015 patients enrolled from March 2010 to July 2011 – –5 year follow-up 44 centers - 12 countries in Western Europe, Asia and South America All centers had conducted at least 40 TAVI procedures prior to the study and had Heart Team in place Clinical endpoints reported according to Valve Academic Research Consortium (VARC)

7 INTERNATIONAL. CAUTION: For distribution only in markets where CoreValve® is approved. Not for distribution in U.S., Canada or Japan. Medtronic, Inc. 2011. All Rights Reserved. CoreValve ADVANCE | Primary Endpoint Primary Endpoint- Major Adverse Cardiac & Cerebrovascular Events (MACCE) at 30-days post procedure. MACCE defined as a composite of All cause mortality Myocardial Infarction (Q-wave and non-Q-wave) Emergent cardiac surgery or percutaneous re-intervention Stroke Clinical endpoints reported according to VARC All-cause and Cardiovascular Mortality Myocardial Infarctions Stroke Life Threatening Bleeding Major Vascular Complications Acute Kidney Injury

8 INTERNATIONAL. CAUTION: For distribution only in markets where CoreValve® is approved. Not for distribution in U.S., Canada or Japan. Medtronic, Inc. 2011. All Rights Reserved. CoreValve ADVANCE | Study Oversight 100% of all Patients were monitored All Primary Endpoint events adjudicated by an Independent Clinical Events Committee (CEC) Consisting of TAVI- experienced Interventional Cardiologists and Cardiac Surgeon All Cerebrovascular events adjudicated by an Independent Neurologist Adjudication of events utilized all available relevant source documents; including neuroimaging and systematic NIH Stroke Scale assessments Core Laboratory Systematic review and assessment of ECG’s and Procedural Angiograms

9 INTERNATIONAL. CAUTION: For distribution only in markets where CoreValve® is approved. Not for distribution in U.S., Canada or Japan. Medtronic, Inc. 2011. All Rights Reserved. CoreValve ADVANCE | Baseline Characteristics

10 INTERNATIONAL. CAUTION: For distribution only in markets where CoreValve® is approved. Not for distribution in U.S., Canada or Japan. Medtronic, Inc. 2011. All Rights Reserved. CoreValve ADVANCE | Procedural Results

11 INTERNATIONAL. CAUTION: For distribution only in markets where CoreValve® is approved. Not for distribution in U.S., Canada or Japan. Medtronic, Inc. 2011. All Rights Reserved. CoreValve ADVANCE | Valve Performance

12 INTERNATIONAL. CAUTION: For distribution only in markets where CoreValve® is approved. Not for distribution in U.S., Canada or Japan. Medtronic, Inc. 2011. All Rights Reserved. CoreValve ADVANCE | Symptom Status

13 INTERNATIONAL. CAUTION: For distribution only in markets where CoreValve® is approved. Not for distribution in U.S., Canada or Japan. Medtronic, Inc. 2011. All Rights Reserved. CoreValve ADVANCE | 30-day Outcomes

14 INTERNATIONAL. CAUTION: For distribution only in markets where CoreValve® is approved. Not for distribution in U.S., Canada or Japan. Medtronic, Inc. 2011. All Rights Reserved. CoreValve ADVANCE | 6-month Survival

15 INTERNATIONAL. CAUTION: For distribution only in markets where CoreValve® is approved. Not for distribution in U.S., Canada or Japan. Medtronic, Inc. 2011. All Rights Reserved. CoreValve ADVANCE | 6-month Survival

16 INTERNATIONAL. CAUTION: For distribution only in markets where CoreValve® is approved. Not for distribution in U.S., Canada or Japan. Medtronic, Inc. 2011. All Rights Reserved. CoreValve ADVANCE | 6-month Survival

17 INTERNATIONAL. CAUTION: For distribution only in markets where CoreValve® is approved. Not for distribution in U.S., Canada or Japan. Medtronic, Inc. 2011. All Rights Reserved. CoreValve ADVANCE | 6-month Stroke

18 INTERNATIONAL. CAUTION: For distribution only in markets where CoreValve® is approved. Not for distribution in U.S., Canada or Japan. Medtronic, Inc. 2011. All Rights Reserved. Summary and Conclusions The CoreValve ADVANCE study, which is the largest, multicenter, prospective, fully monitored TAVI study, shows that treatment of ‘real world’ inoperable and frail, high-risk patients with the Medtronic CoreValve is: Safe Associated with: an improvement in aortic valve function low stroke and mortality rates at 1 month and 6 months follow-up

19 INTERNATIONAL. CAUTION: For distribution only in markets where CoreValve® is approved. Not for distribution in U.S., Canada or Japan. Medtronic, Inc. 2011. All Rights Reserved. Thank You CoreValve ADVANCE Study Centers

20 INTERNATIONAL. CAUTION: For distribution only in markets where CoreValve® is approved. Not for distribution in U.S., Canada or Japan. Medtronic, Inc. 2011. All Rights Reserved. CoreValve ADVANCE | 30-day Survival 1. Meredith I.T. 12 Month Results from ANZ CoreValve TAV Study. Presented at: TCT 2011. 2. Cribier A. FRANCE II Multicenter TAVR Registry. Presented at: TCT 2011. 3. Bosmans J. Belgian TAVI Registry. Presented at: London Valves 2011. 4. Moat N.E., et al. JACC. 2011;58. 5. Petronio AS. Italian Registry. Presented at: EuroPCR 2010.

21 INTERNATIONAL. CAUTION: For distribution only in markets where CoreValve® is approved. Not for distribution in U.S., Canada or Japan. Medtronic, Inc. 2011. All Rights Reserved. CoreValve is a registered trademark of Medtronic CV Luxembourg S.a.r.l. For more information and a complete list of adverse events, warning and contraindications reference CoreValve ® IFU.

Download ppt "INTERNATIONAL. CAUTION: For distribution only in markets where CoreValve® is approved. Not for distribution in U.S., Canada or Japan. Medtronic, Inc. 2011."

Similar presentations

Thirty-day Outcomes from the Multi-centre European Pivotal Trial for Transapical Transcatheter Aortic Valve Implantation with a Self-expanding Prosthesis.

Thirty-day Outcomes from the Multi-centre European Pivotal Trial for Transapical Transcatheter Aortic Valve Implantation with a Self-expanding Prosthesis.
INTERNATIONAL. CAUTION: For distribution only in markets where CoreValve ® has been approved. The CoreValve ® System is not currently approved in the USA,

INTERNATIONAL. CAUTION: For distribution only in markets where CoreValve ® has been approved. The CoreValve ® System is not currently approved in the USA,
STS 2015 John V. Conte, MD Professor of Surgery Johns Hopkins University School of Medicine On Behalf of the CoreValve US Investigators Transcatheter Aortic.

STS 2015 John V. Conte, MD Professor of Surgery Johns Hopkins University School of Medicine On Behalf of the CoreValve US Investigators Transcatheter Aortic.
INTERNATIONAL CAUTION: For distribution only in markets where Engager has been approved. Not approved in the USA, Canada, or Japan. Medtronic Engager Transcatheter.

INTERNATIONAL CAUTION: For distribution only in markets where Engager has been approved. Not approved in the USA, Canada, or Japan. Medtronic Engager Transcatheter.
INTERNATIONAL. CAUTION—For distribution only in markets where CoreValve has been approved. Not approved in the USA, Canada or Japan. The information in.

INTERNATIONAL. CAUTION—For distribution only in markets where CoreValve has been approved. Not approved in the USA, Canada or Japan. The information in.
INTERNATIONAL. CAUTION: For distribution only in markets where CoreValve® is approved. Not for distribution in U.S., Canada or Japan. Medtronic, Inc. 2012.

INTERNATIONAL. CAUTION: For distribution only in markets where CoreValve® is approved. Not for distribution in U.S., Canada or Japan. Medtronic, Inc
Stephen Brecker St. George’s Hospital, London, United Kingdom S Mealing, J Eaton, M Sculpher Oxford Outcomes (ICON), Oxford, United Kingdom Johan Bosmans.

Stephen Brecker St. George’s Hospital, London, United Kingdom S Mealing, J Eaton, M Sculpher Oxford Outcomes (ICON), Oxford, United Kingdom Johan Bosmans.
When Does Baseline Left Ventricular Function Influence Survival Post Transcatheter Aortic Valve Implantation? —The CoreValve Australia New Zealand Study.

When Does Baseline Left Ventricular Function Influence Survival Post Transcatheter Aortic Valve Implantation? —The CoreValve Australia New Zealand Study.
Georg Nickenig, Universitatsklinikum Bonn, Germany Jan-Malte Sinning, Universitatsklinikum Bonn, Germany Jan Kovac, Glenfield Hospital, Leicester, UK Peter.

Georg Nickenig, Universitatsklinikum Bonn, Germany Jan-Malte Sinning, Universitatsklinikum Bonn, Germany Jan Kovac, Glenfield Hospital, Leicester, UK Peter.
Three-year clinical and echocardiographic follow-up of aortic stenosis patients implanted with a self-expending bioprosthesis Sabine Bleiziffer German.

Three-year clinical and echocardiographic follow-up of aortic stenosis patients implanted with a self-expending bioprosthesis Sabine Bleiziffer German.
ACC 2015 Jae K. Oh, MD On Behalf of the US CoreValve Investigators Remodeling of Self-Expanding Transcatheter Aortic Valve Is Responsible for Regression.

ACC 2015 Jae K. Oh, MD On Behalf of the US CoreValve Investigators Remodeling of Self-Expanding Transcatheter Aortic Valve Is Responsible for Regression.
ACC 2015 Michael J Reardon, MD, FACC On Behalf of the CoreValve US Investigators A Randomized Comparison of Self-expanding Transcatheter and Surgical Aortic.

ACC 2015 Michael J Reardon, MD, FACC On Behalf of the CoreValve US Investigators A Randomized Comparison of Self-expanding Transcatheter and Surgical Aortic.
Lessons from TAVR Randomized Trials and Registries E Murat Tuzcu, MD Professor of Medicine Cleveland Clinic Financial disclosures: None PARTNER Executive.

Lessons from TAVR Randomized Trials and Registries E Murat Tuzcu, MD Professor of Medicine Cleveland Clinic Financial disclosures: None PARTNER Executive.
Long-Term Outcomes Using a Self- Expanding Bioprosthesis in Patients With Severe Aortic Stenosis Deemed Extreme Risk for Surgery: Two-Year Results From.

Long-Term Outcomes Using a Self- Expanding Bioprosthesis in Patients With Severe Aortic Stenosis Deemed Extreme Risk for Surgery: Two-Year Results From.
One Year Outcomes in Real World Patients Treated with Transcatheter Aortic Valve Implantation The ADVANCE Study Axel Linke University of Leipzig Heart.

One Year Outcomes in Real World Patients Treated with Transcatheter Aortic Valve Implantation The ADVANCE Study Axel Linke University of Leipzig Heart.
INTERNATIONAL. CAUTION: For distribution only in markets where CoreValve® is approved. Not for distribution in U.S., Canada or Japan. Medtronic, Inc. 2011.

INTERNATIONAL. CAUTION: For distribution only in markets where CoreValve® is approved. Not for distribution in U.S., Canada or Japan. Medtronic, Inc
University Heart Center Hamburg

University Heart Center Hamburg
TAVR Pearls Addressing the Shortcomings of the Current TAVR Generation

TAVR Pearls Addressing the Shortcomings of the Current TAVR Generation
A shifting paradigm of care: Advances in transcatheter heart valve procedures Sandra Lauck MSN, RN, CCN(C) Clinical Nurse Specialist, Arrhythmia Management.

A shifting paradigm of care: Advances in transcatheter heart valve procedures Sandra Lauck MSN, RN, CCN(C) Clinical Nurse Specialist, Arrhythmia Management.
PARTNER Objective To compare surgical aortic valve replacement (AVR) with transcatheter aortic valve replacement (TAVR) in high-risk patients with severe.

PARTNER Objective To compare surgical aortic valve replacement (AVR) with transcatheter aortic valve replacement (TAVR) in high-risk patients with severe.

Similar presentations

Ads by Google